In 2022, out of the 167 million individuals with employer-sponsored insurance, 3.4 million utilized at least one of the first 10 medications earmarked for Medicare price negotiations, according to a recent analysis. The drug most commonly used by those with employer-sponsored health insurance was Jardiance, which is prescribed for diabetes and heart failure, with over 911,000 enrollees using it.

This analysis leverages the Merative MarketScan 2022 commercial claims data to estimate the number of enrollees in the employer-sponsored insurance sector who use one or more of the ten drugs chosen for Medicare Part D price negotiations.

The complete analysis and additional information regarding health costs can be found on the Peterson-KFF Health System Tracker, a comprehensive online resource aimed at monitoring and evaluating the performance of the U.S. healthcare system.